Compare Mongodb Inc (MDB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Recursion Pharmaceuticals Inc — how do they compare? Mongodb Inc trades at $312 (market cap $26.01B), while Recursion Pharmaceuticals Inc trades at $3.05 (market cap $1.53B). The key difference: Mongodb Inc is far larger — about 17× Recursion Pharmaceuticals Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MDB | RXRX | |
|---|---|---|
Market Cap | $26.01B | $1.53B |
Sector | Technology | Health |
52-Week High | $440.25 | $6.79 |
52-Week Low | $201.08 | $2.84 |
Enterprise Value | $23.61B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $324.44, up 3.88% today, with strong analyst support (82% buy ratings) and a $400.39 consensus price target. The stock shows bearish technical signals but has consistently beaten earnings expectations, with Q1 2026 EPS of $1.32 surpassing the $1.19 estimate. Revenue growth remains robust at $2.01B for 2025, though profitability challenges persist with a negative net margin of -1.12%.
MDB presents a growth investment opportunity with accelerating revenue and improving margins, but faces execution risks and competitive pressures. The stock's premium valuation (P/S 9.77) requires sustained high growth, while negative cash flow and ongoing profitability concerns warrant caution despite Wall Street optimism.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
